对ROS1抑制剂的差异网络分析透露了通过共同向PYK2的lorlatinib多药学
Yi Liao1, Lily L Remsing Rix1, Xueli Li1
1Department of Drug Discovery, H. Lee Moffitt Cancer Center & Research Institute, Tampa, FL 33612, USA.
Cell chemical biology
|October 17, 2023
概括
洛拉提尼布通过独特地抑制焦点粘附信号传递,显示出对ROS1阳性肺癌的优越效力. 这种氨酸激酶抑制剂 (TKI) 针对ROS1和PYK2进行向,这表明肺癌的新型组合疗法.
科学领域:
- 在瘤学瘤学.
- 药理学 药理学是指药理学的学科.
- 分子生物学分子生物学
背景情况:
- 存在多种类型的氨酸激酶抑制剂 (TKIs) 用于类似的适应症,但它们的比较疗效和非目标效应往往不清楚.
- 与预期目标合作的未被识别的目标可以影响TKI在癌症治疗中的有效性.
研究的目的:
- 为了比较各种ROS1 TKIs对ROS1融合阳性肺癌的细胞功效.
- 阐明差异性TKI疗效的潜在机制,并确定潜在的药物组合策略.
主要方法:
- 对细胞活力,ROS1自酸化和激酶活性的ROS1TKI进行比较分析.
- 量化化学和蛋白组学与差异网络分析相结合.
- 通过药理学探针,RNA干扰和CRISPR-Cas9淘汰的功能验证.
主要成果:
- 洛拉提尼布与其他ROS1TKI相比显示出不成比例的更高的细胞效能.
- 洛拉提尼布独特地影响了焦点粘附信号,揭示了多药理学机制.
- 确定了lorlatinib对ROS1和PYK2的双重向,涉及与SRC.的复合物.
- 将洛拉提尼布与SRC抑制剂结合使用显示出显著的协同效应.
结论:
- 系统药理学和网络分析可以剖析TKI复杂的多药理学机制.
- 洛拉提尼布对ROS1和PYK2的双重向为肺癌的联合治疗提供了理由.
- 这种方法可以设计合理的药物组合,以改善癌症治疗结果.
相关概念视频
02:57Targeted Cancer Therapies
7.7K
The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
There are several types of targeted therapies against...
7.7K
01:26Receptor Tyrosine Kinases
13.0K
Receptor tyrosine kinases or RTKs are membrane-bound receptors that phosphorylate specific tyrosine on protein substrates. RTKs regulate cellular growth, differentiation, survival, and migration. They contain an extracellular ligand binding domain, a transmembrane domain, and a cytosolic tail with intrinsic kinase activity. Several extracellular signaling molecules activate RTKs in one or more ways and relay the signal downstream. Ligands such as platelet-derived growth factor (PDGF) or...
13.0K
01:22PI3K/mTOR/AKT Signaling Pathway
3.6K
The mammalian target of rapamycin (mTOR) is a serine/threonine kinase that regulates growth, proliferation, and cell survival in response to hormones, growth factors, or nutrient availability. This kinase exists in two structurally and functionally distinct forms: mTOR complex 1 (mTORC1) and mTOR complex 2 (mTORC2). The first form (mTORC1) is composed of a rapamycin-sensitive Raptor and proline-rich Akt substrate, PRAS40. In contrast, mTORC2 consists of a...
3.6K
01:27Transducer Mechanism: Enzyme-Linked Receptors
2.5K
Enzyme-linked receptors are cell-surface receptors acting as an enzyme or associating with an enzyme intracellularly. They make excellent drug targets. Drugs can bind to the extracellular ligand-binding domain or directly affect their enzymatic domain and alter their activity.
Major types that are helpful drug targets include:
Major types that are helpful drug targets include:
2.5K
01:19Interactions Between Signaling Pathways
6.3K
Signaling cascades usually lack linearity. Multiple pathways interact and regulate one another, allowing cells to integrate and respond to diverse environmental stimuli.
Convergence and divergence, and cross-talk between signaling pathways
Two distinct signaling pathways can converge on a single functional unit, which may either be a single protein or a complex of proteins. The response is either functionally distinct or synergistic between the two pathways but different from the response...
Convergence and divergence, and cross-talk between signaling pathways
Two distinct signaling pathways can converge on a single functional unit, which may either be a single protein or a complex of proteins. The response is either functionally distinct or synergistic between the two pathways but different from the response...
6.3K